Challenging Cases in RRMM Symposium Replay

Guide to Challenging Cases in Relapsed/Refractory Multiple Myeloma: Improving Practice in 2017
Guide to Challenging Cases in Relapsed/Refractory Multiple Myeloma: Improving Practice in 2017
CME, CPE, CNE
Robert Z. Orlowski, MD, PhD; Ajay K. Nooka, MD, MPH, FACP; Peter M. Voorhees, MD
Release Date: October 06, 2017
Expiration Date: October 06, 2018

Relapsed/refractory multiple myeloma (RRMM) is one of the most challenging hematologic malignancies that oncology practitioners will treat. Often, patients with RRMM have significant comorbidities and multiple prior treatment failures, all of which complicate both therapeutic decisions and subsequent patient management.

In this activity, adapted from a live symposium held in conjunction with a clinical hematologic malignancies meeting in September 2017, a panel of internationally known experts in myeloma discuss new and emerging therapeutic strategies for RRMM. Participants will gain a greater understanding of how to effectively address the real-world challenges of disease progression, comorbid conditions, high-risk factors, and treatment-emergent adverse events in their patients with RRMM.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Inc. and Celgene Corporation.
Begin, Earn CreditView Only, No Credit